Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2021-04-29 Director's Dealing
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-04-29 English
S-1
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, as indicated by multiple references to 'Form S-1', 'Registration Statement', and 'Securities Act of 1933'. It is a detailed prospectus related to the registration of securities for public offering, including information about the company, the offering, risk factors, use of proceeds, selling stockholders, and other disclosures typical of an S-1 filing. This type of document is a regulatory filing used to register securities for sale and is not an annual report, earnings release, or any other financial report. It is not a report publication announcement either, as it contains substantive information and is not merely announcing the availability of a report. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-04-28 English
FORM 4 SUBMISSION
Director's Dealing
2021-04-21 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Relay Therapeutics, Inc. It reports the entry into a definitive material agreement, specifically a merger agreement with ZebiAI Therapeutics, Inc. The document details the terms of the merger, including consideration, conditions, and approvals. It also references a press release and a slide presentation related to the merger. The primary content is about a merger transaction announcement and related disclosures. This fits the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. The document is not a full annual or quarterly report, audit report, earnings release, or other categories. Therefore, the appropriate classification is M&A Activity (TAR). The confidence in this classification is high given the clear merger agreement and related disclosures.
2021-04-16 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as a "Definitive Additional Materials" related to the Annual Meeting of Stockholders. It includes information about the meeting date, voting instructions, director nominations, and ratification of the independent auditor. The content is focused on soliciting shareholder votes and providing proxy materials rather than presenting financial results or detailed reports. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is about 5,047 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is PSI.
2021-04-07 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.